



NEWS RELEASE

PRIVATE OFFERING RAISES OVER \$4 MILLION

December 20, 2006 (Woodstock, Georgia) – Tissue Regeneration Technologies (TRT) today announced that it has closed its second private offering. This offering, which offered membership units in the company for \$2.00 each, raised over \$4 Million in additional capital and added 110 new members!

TRT achieved several milestones during the course of the offering, fueling interest in the company and its technology and generating significant capital investment. Among them were:

- commencement of FDA clinical trials for the treatment of diabetic foot ulcers using TRT's DermaGold™ MultiWave™ device;
- FDA clearance to market TRT's LithoGold™ lithotripsy device for the treatment of kidney and ureter stones;
- creation of Cardiac Regeneration Technologies, LLC, a subsidiary formed to oversee the research utilizing TRT's MultiWave technology to treat ischemic heart disease and other cardiovascular disorders (and which raised an additional \$1.7 million in capital);
- award of \$1 Million in Federal appropriations for the Combat Wound Initiative; and
- placing its 150th shockwave device under service contract.

To date, the company has raised approximately \$10 Million in private capital mainly to fund FDA studies and private research in seeking approval to market its patent-pending revolutionary MultiWave technology and devices. "We are extremely pleased with the results of the research that our company is funding, such as our cardiac studies in Europe. We believe our technology has the capability to revolutionize treatment in numerous fields of medicine, and we are thrilled to be on the leading edge of such medical advancement," stated John Warlick, TRT president.

Based on projections for LithoGold sales, increased market share in the service industry and other factors, TRT, a two-year-old medical start-up, expects to be profitable by mid-2007, despite the substantial cost of funding FDA studies and clinical research.

Because of TRT's growing presence in the marketplace and various cooperative overtures being made by major players in the industry, a private follow-on offering is expected to commence in Q1 2007 at \$3.00 per unit.

About TRT

TRT is a leading-edge health care company that believes in "doing well by doing good." Our state-of-the-art medical devices utilize MultiWave™ technology (a combination of heat, electromagnetic, acoustic, and light energies) to provide non-invasive and minimally invasive treatment for numerous pathological conditions, including chronic wounds, multiple periodontal applications, pseudoarthrosis and other avascular conditions of the bone, and ischemic heart disease. TRT is headquartered in suburban Atlanta, Georgia from which we operate our urology

division, Shockwave Technical Service, and our cardiac subsidiary, Cardiac Regeneration Technologies. Production of our devices is handled by TRT's manufacturing subsidiary, MTS Europe GmbH, located in Lake Constance, Germany. Our devices are currently CE approved and distributed in approximately 20 countries throughout North America, Europe, Asia, Africa and South America. For more information, please visit the company's website at www.trtlc.com.

Contact information: TRT, Julie Dodd, (770) 966-1315 or jdodd@trtlc.com